ASH 2016 | Trial of vadastuximab talirine combined with 7+3 induction therapy for newly diagnosed AML patients

Name: Trial of vadastuximab talirine combined with 7+3 induction therapy for newly diagnosed AML patients
Uploaded: 2016-12-03T00:00:00.000Z
Duration: 11 min 55 s
Description: Press brief by Harry Erba, MD, PhD, of The University of Alabama At Birmingham, Birmingham, AL, on a Phase 1b Study of vadastuximab talirine in combination with 7+3 induction therapy for patients with newly diagnosed acute myeloid leukemia (AML) at the 2016 American Society of Hematology (ASH) Annual Meeting, held in San Diego, CA.

Harry Erba • 3 Dec 2016

ASH 2016

Acute Myeloid Leukemia Antibodies Vadastuximab talirine

Press brief by Harry Erba, MD, PhD, of The University of Alabama At Birmingham, Birmingham, AL, on a Phase 1b Study of vadastuximab talirine in combination with 7+3 induction therapy for patients with newly diagnosed acute myeloid leukemia (AML) at the 2016 American Society of Hematology (ASH) Annual Meeting, held in San Diego, CA.